Odronextamab in Low Tumor Volume Advanced FL

This prospective, phase 2, single-arm, open label study is to evaluate the safety and effectiveness of Odronextemab in participants with previously untreated Follicular Lymphoma (FL). Odronextemab is a type of immunotherapy is a cancer treatment that uses the body's own immune system to fight cancer cells. The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, Computerized Tomography (CT) scans, Positron Emission (PET) scans, echocardiograms (ECGs), bone marrow biopsies and aspirations, and tumor biopsies. The U.S. Food and Drug Administration (FDA) has not approved odronextamab as a treatment for Follicular Lymphoma. Participants will receive the study drug for up to 6 cycles, or 126 days, and will be followed for up to 15 years. It is expected that about 35 people will take part in this research study. Regeneron Pharmaceuticals, Inc. is supporting this research study by providing the study drug, odronextamab and funding for this study.